[Federal Register Volume 81, Number 140 (Thursday, July 21, 2016)]
[Notices]
[Pages 47396-47397]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-17182]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2016-N-0001]
Advisory Committee; Science Board to the Food and Drug
Administration, Renewal
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; renewal of advisory committee.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
renewal of the Science Board to the Food and Drug Administration by the
Commissioner of Food and Drugs (the Commissioner). The Commissioner has
determined that it is in the public interest to renew the Science Board
to the Food and Drug Administration for an additional 2 years beyond
the charter expiration date. The new charter will be in effect until
June 26, 2018.
DATES: Authority for the Science Board to the Food and Drug
Administration will expire on June 26, 2018, unless the Commissioner
formally determines that renewal is in the public interest.
FOR FURTHER INFORMATION CONTACT: Rakesh Raghuwanshi, Office of the
Chief Scientist, Office of the Commissioner, Food and Drug
Administration, Bldg. 1, Rm. 3309, 10903 New Hampshire Ave., Silver
Spring, MD 20993, 301-796-4769, [email protected].
SUPPLEMENTARY INFORMATION: Pursuant to 41 CFR 102-3.65 and approval by
the Department of Health and Human Services pursuant to 45 CFR part 11
and by the General Services Administration, FDA is announcing the
renewal of the Science Board to the Food and Drug Administration. The
committee is a discretionary Federal advisory committee established to
provide advice to the Commissioner. The Science Board advises the
Commissioner or designee in discharging responsibilities as they relate
to helping to ensure safe and effective drugs for human use and, as
required, any other product for which FDA has regulatory
responsibility. The Science Board shall provide advice to the
Commissioner and other appropriate officials on specific complex
scientific and technical issues important to FDA and its mission,
including emerging issues within the scientific community.
Additionally, the Science Board will provide advice that supports the
Agency in keeping pace with technical and scientific developments,
including in regulatory science; and input into the Agency's research
agenda; and on upgrading its scientific and research facilities and
training opportunities. It will also provide, where requested, expert
review of Agency-sponsored intramural and extramural scientific
research programs.
The Committee shall consist of a core of 21 voting members
including a Chair and Co-Chair. The members, Chair and Co-Chair are
selected by the Commissioner or designee from among authorities
knowledgeable in the fields of food science, safety, and nutrition;
chemistry; pharmacology; translational and clinical medicine and
research; toxicology; biostatistics; medical devices; imaging;
robotics; cell and tissue based products; regenerative medicine; public
health and epidemiology; international health and regulation; product
safety; product manufacturing sciences and quality; and other
scientific areas relevant to FDA regulated products such as systems
biology, informatics, nanotechnology, and combination products. Members
[[Page 47397]]
will be invited to serve for overlapping terms of up to 4 years. Almost
all non-Federal members of this committee serve as Special Government
Employees. The core of voting members may include one technically
qualified member, selected by the Commissioner or designee, who is
identified with consumer interests and is recommended by either a
consortium of consumer-oriented organizations or other interested
persons. The Committee may also include technically qualified federal
members.
Further information regarding the most recent charter and other
information can be found at http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/ScienceBoardtotheFoodandDrugAdministration/ucm115356.htm or by contacting the Designated Federal Officer (see FOR
FURTHER INFORMATION CONTACT). In light of the fact that no change has
been made to the committee name or description of duties, no amendment
will be made to 21 CFR 14.100.
This document is issued under the Federal Advisory Committee Act (5
U.S.C. app.). For general information related to FDA advisory
committees, please visit us at http://www.fda.gov/AdvisoryCommittees/default.htm.
Dated: July 15, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016-17182 Filed 7-20-16; 8:45 am]
BILLING CODE 4164-01-P